Nurse Practitioner in Deckerville, MI Accepting Medicare
4 Nurse Practitioner nurses found. Showing 1 - 4
 Mrs. Carrie V Eugster, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2433 Black River St, Deckerville, MI 48427 Phone: 810-376-2885 Fax: 810-376-8301 |
 Keith Davidson, NP-C Nurse Practitioner - Adult Health Medicare: Accepting Medicare Assignments Practice Location: 2433 Black River St, Deckerville, MI 48427 Phone: 810-376-2885 |
Lindsey Bulgrien, NP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 2433 Black River St, Deckerville, MI 48427 Phone: 810-376-2885 Fax: 810-376-8301 |
Mrs. Judith Ann Kaszyca, NURSE PRACTITONER Nurse Practitioner - Adult Health Medicare: Not Enrolled in Medicare Practice Location: 3532 Main St, Deckerville, MI 48427 Phone: 810-376-3100 Fax: 810-376-8311 |
News Archive
First Edition: September 14, 2012
Today's headlines include stories detailing the politics stirred up by GOP vice presidential candidate Paul Ryan's return to Capitol Hill, as well as reports about new poll numbers and the latest about how health issues are playing on the campaign trail.
CMS awards $230M task order contract to CSC
CSC announced today that the Centers for Medicare & Medicaid Services Office of Clinical Standards and Quality awarded the company a task order to migrate key information technology systems to a new service-oriented architecture. The contract, which was awarded during CSC's fiscal 2011 second quarter, has a six-month base period and six one-year options, bringing the estimated 78-month contract value to $230 million.
Manipulation of proliferation and differentiation of human bone marrow derived neural stem cells in vitro and in vivo
Stem cells taken from adult human bone marrow have been manipulated by scientists at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center to generate aggregates of cells called spheres that are similar to those derived from neural stem cells of the brain.
Omeros initiates enrollment in OMS824 Phase 1 trial for schizophrenia and Huntington's
Omeros Corporation today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.
Extend Health ranks No. 94 on 2010 'Inc. 500' list of fastest-growing private companies
Inc. magazine has ranked Extend Health, Inc. No. 94 on its 29th annual Inc. 500, which was released today. This is the first time the company applied for inclusion on this exclusive list of the nation's fastest-growing private companies. The ranking is based on a 2,579% increase in sales over the past three years, leading to revenue of $36.6 million in 2009. Based on its 2009 revenue, Extend Health would rank No. 14 among the top 100 companies on the 2010 Inc. 500 list.
› Verified 1 days ago